Literature DB >> 21550686

Expression of thymidylate synthase, orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in thymic epithelial tumors.

Kyoichi Kaira1, Masakuni Serizawa, Yasuhiro Koh, Satoru Miura, Rieko Kaira, Masato Abe, Kazuo Nakagawa, Yasuhisa Ohde, Takehiro Okumura, Haruyasu Murakami, Asuka Tsuya, Yukiko Nakamura, Tateaki Naito, Toshiaki Takahashi, Haruhiko Kondo, Takashi Nakajima, Masahiro Endo, Nobuyuki Yamamoto.   

Abstract

BACKGROUND: It remains unclear whether thymidylate synthase (TS), orotate phosphoribosyltransferase (OPRT) and dihydropyrimidine dehydrogenase (DPD) expressions are associated with the pathogenesis of thymic epithelial tumors. Therefore, we investigated the expression of TS, OPRT and DPD in thymic epithelial tumors. PATIENTS AND METHODS: Fifty-six patients with thymic epithelial tumors were included in this study. Tumors sections were stained by immunohistochemistry for TS, OPRT, DPD, microvessel density (MVD) determined by CD34, and p53. We also conducted in vitro study of TS, OPRT and DPD expression using thymic carcinoma, thymic tumor and thymic fibroblast cell lines.
RESULTS: TS, OPRT and DPD were expressed in 61%, 48% and 41%, respectively. High grade malignancy is significantly associated with higher expression of TS, OPRT and DPD in thymic epithelial tumors. These biomarkers were closely associated with p53 and MVD, and the overexpression of TS and DPD was a prognostic marker for predicting poor outcome in univariate analysis. Our in vitro study showed that marked overexpression of TS and OPRT was observed in thymic carcinoma cells, but not in thymic tumor cells, or thymic fibroblast cells.
CONCLUSIONS: The expression of TS, OPRT and DPD was closely related to the grade of malignancy in thymic epithelial tumors. A positive expression of TS, DPD and OPRT might be an important factor in predicting the effectiveness of 5-FU based chemotherapy in this disease.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21550686     DOI: 10.1016/j.lungcan.2011.04.001

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  7 in total

1.  The long-term survival of a thymic carcinoma patient treated with S-1: a case report and literature review.

Authors:  Hisashi Tanaka; Takeshi Morimoto; Kageaki Taima; Yoshihito Tanaka; Kunihiko Nakamura; Akihito Hayashi; Akira Kurose; Ken Okumura; Shingo Takanashi
Journal:  Onco Targets Ther       Date:  2013-12-27       Impact factor: 4.147

Review 2.  Orotate phosphoribosyltransferase is overexpressed in malignant pleural mesothelioma: Dramatically responds one case in high OPRT expression.

Authors:  Yoichiro Hamamoto; Shinjiro Takeoka; Atsuto Mouri; Munehisa Fukusumi; Kazushige Wakuda; Tatsuya Ibe; Chie Honma; Yoshihito Arimoto; Kazuaki Yamada; Miyuki Wagatsuma; Akito Tashiro; Shingo Kamoshida; Mitsuhiro Kamimura
Journal:  Rare Dis       Date:  2016-04-05

3.  Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma.

Authors:  Yusuke Okuma; Yukio Hosomi; Shingo Miyamoto; Masahiko Shibuya; Tatsuru Okamura; Tsunekazu Hishima
Journal:  BMC Cancer       Date:  2016-02-25       Impact factor: 4.430

4.  A novel intraperitoneal therapy for gastric cancer with DFP-10825, a unique RNAi therapeutic targeting thymidylate synthase, in a peritoneally disseminated xenograft model.

Authors:  Hidenori Ando; Masakazu Fukushima; Kiyoshi Eshima; Taichi Hasui; Taro Shimizu; Yu Ishima; Cheng-Long Huang; Hiromi Wada; Tatsuhiro Ishida
Journal:  Cancer Med       Date:  2019-10-14       Impact factor: 4.452

5.  Comprehensive expressional analysis of chemosensitivity-related markers in large cell neuroendocrine carcinoma of the lung.

Authors:  Yoichi Ohtaki; Kyoichi Kaira; Toshiki Yajima; Bilguun Erkhem-Ochir; Osamu Kawashima; Mitsuhiro Kamiyoshihara; Hitoshi Igai; Ryoichi Onozato; Takashi Ibe; Takayuki Kosaka; Seshiru Nakazawa; Toshiteru Nagashima; Tetsunari Oyama; Ken Shirabe
Journal:  Thorac Cancer       Date:  2021-08-28       Impact factor: 3.500

6.  MicroRNA-433 negatively regulates the expression of thymidylate synthase (TYMS) responsible for 5-fluorouracil sensitivity in HeLa cells.

Authors:  Keisuke Gotanda; Takeshi Hirota; Nozomi Matsumoto; Ichiro Ieiri
Journal:  BMC Cancer       Date:  2013-08-02       Impact factor: 4.430

7.  Efficacy of pemetrexed-based regimen in relapsed advanced thymic epithelial tumors and its association with thymidylate synthetase level.

Authors:  Xinyu Qian; Zhengbo Song
Journal:  Onco Targets Ther       Date:  2016-07-22       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.